Coexistence of diabetes mellitus and Graves' disease may be classified into either an immunologicallyrelated or an incidental phenomenon.
. In such cases, considering both diseases arise from an autoimmune process, one can assume that the subjects would have common genetic backgrounds. HLA locus is one such candidate gene [5] [6] [7] , although other genes seem to remain undetected. Not all subjects presenting both diseases seem to share such common genetic backgrounds, because many of the subjects have apparent type 2 diabetes, a non-autoimmune disease. In those subjects, both diseases might coexist incidentally.
Glutamic acid decarboxylase (GAD) is postulated to be a primary antigen for autoimmunity toward pancreatic B cells [8, 9] . Positive anti-GAD antibody (GAD-Ab) is proved to be a sensitive marker for diagnosis of the autoimmunity toward B cell and type 1 diabetes [10] [11] [12] . It was suggested that type 1 diabetic subjects with autoimmune thyroid diseases (AITD) may have different clinical and immunological features, as compared with those without AITD [13, 14}. Most strikingly, long-standing and high levels of GAD-Ab were demonstrated in Japanese subjects with type 1 diabetes and AITD [15] . Thus, GAD-Ab measurement might be a simple and sensitive tool for diagnosis of the immunological coexistence of diabetes and AITD, as well as diagnosis of type 1 diabetes.
Coexistence of diabetes mellitus and Graves' disease is not unusual [16, 17] , although the distinct clinical features of the coexistence have not been well described. Thus, to test the hypothesis whether GAD-Ab measurement could discriminate between immunological and incidental coexistence of the two diseases, we investigated detailed clinical charcteristics of Japanese subjects having both diabetes and Graves' disease according to the presence or absence o f GAD-Ab. Between the registration period, sera were obtained after an overnight fast for GADAb assay. The duration of diabetes mellitus and that of Graves' disease at the time of GAD-Ab assay were 11 ± 2 and 10 ± 2 years, respectively. At the same time, samples for HLA-typing (n=51) and for preparation of genomic DNA (n = 43) were collected. All the subjects gave their informed consent to join the present study, and the protocol was approved by the local ethical committee.
Subjects

Subjects and Methods
Diagnosis
Diagnosis of diabetes mellitus was based on the 1985 WHO criteria [18] . An oral glucose tolerance test was performed if judged necessary. When subjective symptoms of hyperglycemia and ketosis were documented, and insulin therapy was subsequently introduced within 6 months since the initial symptoms, the mode of the onset was defined as " abrupt".
Otherwise, the onset was regarded as " gradual". Insulin dependency was judged by clinical necessity of insulin administration, accompanied with decreased serum and/or urinary C-peptide levels, fasting serum C-peptide levels less than 0.16 nmol/l and/or urinary C-peptide less than 6.6 nmol/day [19] . When the insulin-treated subjects did not show significantly decreased C-peptide levels as mentioned above, they were tentatively designated as "insulin requiring" . The evaluation of insulin dependency was repeated if necessary.
Diagnosis of Graves' disease was based on elevated serum thyroid hormone concentrations, undetectable serum thyrotropin, and high levels of serum TRAb. Diffuse thyroidal uptake of 123Iodine or 131Iodine was also confirmed if necessary. When presence of diffuse goiter and palpitation were recorded as initial symptoms of Graves' disease, clinical manifestations were judged as "typical". Otherwise, the manifestation was regarded as "masked", including cases in whom only loss of body weight was recorded.
If the initial diagnosis of both diseases was made within 12 months, it was defined that both diseases occurred "at the same time". AND GRAVES' DISEASE 749
Measurements
When the diagnosis of diabetes mellitus was initially made, fasting serum C-peptide was measured by a radioimmunoassay (RIA) kit (Daiichi-Radioisotope, Tokyo, Japan).
The intra-and inter-assay coefficients of variation were 5.1 and 5.1 %, respectively. At the initial diagnosis of Graves' disease, serum free thyroxine was determined by a RIA kit (Kodak Diagnostics, Tokyo, Japan), and TRAb by a radioreceptor assay kit (Cosmic Corporation, Tokyo, Japan). Anti-thyroglobulin antibody (TGHA) and anti-microsomal antibody (MCHA) were measured by a hemagglutination method (Fuji-Rebio, Tokyo, Japan).
GAD-Ab was measured by a GAD-Ab RIA kit (RIP Anti-GAD Hoechst, Tokyo, Japan) [20] . The intra-and inter-assay coefficients of variation were 3.6 and 5.1 %, respectively. The assay was validated at the GAD-Ab workshops [21, 22] . As mean + 3 SD level of healthy subjects is 8 U/ml [23], we defined the level of 8 U/ml or greater as positive for GADAb. GAD-Ab was also determined in 131 non-diabetic subjects with Graves' disease. HLA-DR locus was typed by the standard microcytotoxicity test as described previously [24] . The data on HLA-DR frequency in Japanese healthy control subjects were also obtained from Ref. 24 . In addition, HLA-DQA1 genotype and cytotoxic T lymphocyte antigen 4 (CTLA-4) gene exon 1 polymorphism (49 A/G) were defined by polymerase chain reaction-restriction fragment length polymorphism using genomic DNA and the primers as described previously [25, 26] . HLA-DQA1 genotype and CTLA-4 gene polymorphism were also determined in 37 and 141 Japanese healthy subjects, respectively.
Statistical analysis
Data were expressed as means ± SE. Unpaired Student's t-test and f-test were used to compare the difference. Fisher's exact probability was calculated by f-test, if necessary. These analyses were performed using StatView 4.5 for the Macintosh (Abacus Concepts, Berkeley, CA). A p value less than 0.05 was considered significant.
Results
GAD-Ab in non-diabetic subjects with Graves' disease GAD-Ab was positive in 2 (1.5%) out of the 131 non-diabetic subjects with Graves' disease alone. The prevalence was comparable to 0.3% (1./323, P = 0.2012) in normal subjects in the literature [20] .
Clinical features of GAD-Ab positive and negative patients The 61 subjects having both diabetes mellitus and Graves' disease were divided into two groups of 14 GAD-Ab positive and 47 negative patients ( Table 1) . The GAD-Ab values of the positive patients were 5862±5148 U/ml. The ages at the examination were younger in the GAD-Ab positive subjects. There was no difference in sex distribution. The onset of diabetes mellitus and that of Graves' disease were significantly earlier in the GAD-Ab positive patients Table 1 . Clinical features of GAD-Ab positive and negative patients than those in the negative patients. In 8 out of the 14 GAD-Ab positive subjects, Graves' disease preceded diabetes mellitus. In the remaining 6 GAD-Ab positive subjects, both diseases were diagnosed at the same time. The preceding diseases were variable in the GAD-Ab negative patients.
Clinical characteristics of diabetes mellitus
There was no difference in the prevalence of positive family history of diabetes mellitus between these two groups ( Table 2 ). Abrupt onset of diabetes was more frequent in the GAD-Ab positive patients, whereas most of the negative patients showed gradual onset. Although past maximal BMI was identical between the two groups, BMI at the onset of diabetes was lower in the GAD-Ab positive patients. In those subjects, fasting serum C-peptide levels were significantly lower, and the frequency of initial insulin therapy was higher.
Among 12 GAD-Ab positive patients manifesting abrupt onset of diabetes, 8 subjects were insulin dependent at the final examinations ( Table 2) . The remaining 4 patients required insulin administration from the onset, but their fasting and post-prandial serum C-peptide levels were 0.19-0.56 and 0.48-2.24 nmol/l at the final examinations, respectively (the observation periods since their onsets were 15-58 months). Thereby, they were diagnosed as insulin-requiring.
Two GAD-Ab positive male patients showing gradual onset of diabetes had come to require insulin therapy after 60 and 70 months since their initial diagnosis of diabetes; one patient fell into insulin dependency and another had remained insulin requiring at the final examinations.
On the other hand, most of the 47 GAD-Ab negative patients remained non-insulin dependent. In the 12 insulin-treated subjects out of the GAD-Ab negative subjects, only 3 subjects were insulin dependent. Table 2 .
Clinical characteristics of diabetes in GAD-Ab positive and negative patients Table 3 . Clinical characteristics of Graves' disease in GAD-Ab positive and negative patients Clinical characteristics of Graves' disease Typical clinical manifestations of Graves' disease were more frequent in the GAD-Ab positive patients, while masked manifestations dominated in the negative patients (Table 3 ). BMI at the onset of Graves' disease was lower in the former subjects. There was no difference in the initial levels of free thyroxine, TRAb, TGHA and MCHA between these two groups.
Immunological studies
In the 13 GAD-Ab positive subjects examined, frequency of HLA-DR 4 was significantly higher than that in the control subjects ( Table 4 ). As no subject had HLA-DR 2 in the GAD-Ab positive subjects, HLA-DR 2 was less frequent in the GAD-Ab positive subjects, as compared with the GAD-Ab negative subjects and the controls. In the GAD-Ab negative subjects, frequency of HLA-DR 4, 9 and 2 was similar to that in the control subjects.
There was also a trend of higher frequency of HLA-DQA1 *03 allele and of lower frequency of DQAI *01 allele in these subjects.
CTLA-4 gene exon 49 polymorphism tended to show a skewed distribution between the GAD-Ab positive and negative patients (P = 0.0736) ( Table 4) . Frequency of G allele was significantly higher in the positive subjects, as compared with that in the negative subjects.
Discussion
The coexistence of diabetes mellitus and Graves' disease is not infrequent, and a few reports in the literature have described the coexistence of both diseases [16, 17] . Since type 1 diabetes and Graves' disease are believed to be caused by an autoimmune process, the coexistence of the two diseases would be classified into either an immunologically-related or an incidental phenomenon.
This aspect of the classification has not been systematically described as far as we know.
Some studies have shown an association of GAD-Ab with Graves' disease [15, 27] , but we failed to replicate the results. Thus, we assumed that GAD-Ab could be a marker of the immunologicallyrelated coexistence of diabetes mellitus and Graves' disease [15] , as well as that of type 1 diabetes [10] [11] [12] . In the present study, we classified the 61 Japanese Table 4 . Immunological studies in GAD-Ab positive and negative patients patients having both diseases into the GAD-Ab positive and negative subjects, and compared these two groups.
In the GAD-Ab positive patients, the onsets of diabetes mellitus and Graves' disease were earlier than those in the negative patients. They had high levels of GAD-Ab, in accordance with the previous report in Japanese [1 5] . Interestingly, in all the GAD-Ab positive subjects studied here, diabetes mellitus had not preceded Graves' disease. In the previous report describing 13 Japanese subjects having both type 1 diabetes and Graves' disease, the same trend was reported: Graves' disease preceded diabetes or was diagnosed almost simultaneously with diabetes in 9 out of the 13 subjects [13] . In the GAD-Ab negative patients, precedence of diabetes was more common, consistent with the previous observations [16, 17] .
Abrupt onset of diabetes was recorded in most of the GAD-Ab positive patients (86%). The rate of abrupt onset was comparable with our observations that 80% of about 300 Japanese subjects with type 1 diabetes who had been registered in our division between 1974-1997 showed typical abrupt onset (S.N. & I.K., unpublished observation). In contrast, gradual onset of diabetes, preserved fasting C-peptide levels, and far lesser frequency of initial insulin therapy were found in the GAD-Ab negative patients.
The clinical courses of diabetes mellitus in the 14 GAD-Ab positive patients were not uniform. Most of the subjects showed abrupt onset of diabetes and insulin dependency was confirmed at the onset, although there were 2 GAD-Ab positive subjects who showed a slowly progressive course. Also, 5 GADAb positive subjects were not definitely insulin dependent at the final examinations despite their continuous requirement of insulin therapy. Further longitudinal observation is necessary to ascertain whether the 5 subjects will progress into insulin dependency. Otherwise, insulin therapy per se may have a beneficial effect on residual B cell function in those subjects, as observed in a preliminary study on Japanese subjects with type 1 diabetes [28] . Most of the 47 GAD-Ab negative patients were non-insulin dependent, although a few GAD-Ab negative subjects showed apparent insulin dependency. This may be explained by the fact that GAD-Ab cannot be found in all cases with type 1 diabetes [10] [11] [12] 29] , especially in subjects with longer duration [20] . It also remains to be elucidated whether additional measurement of other markers of type 1 diabetes, such as ICA or IA-2, could reveal the autoimmunity toward B cell in these subjects.
Typical clinical manifestations of Graves' disease were common in the GAD-Ab positive patients, whereas masked manifestations were frequent in the negative patients despite similar thyroid hormone and TRAb levels. Graves' disease occurred about 16 years later in the latter subjects. Thus, this difference in the clinical manifestations may be explained by a finding that the clinical symptoms of Graves' disease tend to be masked in elderly subjects [30] . In the present study, we found several GADAb negative elderly diabetic subjects with poor glycemic control and a sole symptom of body weight loss, who were subsequently diagnosed as having Graves' disease. Although it is well known that thyrotoxicosis aggravates metabolic control of diabetic subjects [16, 17] , careful attention should be paid not to overlook thyrotoxicosis especially in elderly diabetic subjects.
Finally, several lines of the differences in immunological backgrounds were demonstrated between the GAD-Ab positive and negative patients.
First, HLA-DR 4 was more frequent, and DR 2 was far less in the GAD-Ab positive subjects. These results are consistent with the previous finding on HLA-DR status of type 1 diabetes in Japanese [24] . In contrast, the frequency of HLA-DR 4, 9 and 2 was identical between the GAD-Ab negative subjects and the controls.
HLA-DQA1 alleles also tended to show a skewed distribution between the GAD-Ab positive and negative subjects. Secondly, allelic frequency of CTLA-4 gene polymorphism differed between the GAD-Ab positive and negative subjects. CTLA-4 molecule is an important regulator of activated T cell functions, and is postulated to be involved in modulation of autoimmune process [31] . Several recent studies have shown that CTLA-4 gene polymorphism is associated with both type 1 diabetes and Graves' disease in Caucasians and in Japanese [26, 32, 33] . Further analysis is necessary to elucidate the possible role of CTLA-4 gene polymorphisms in autoimmune polyendocrinopathies, although a single study showed no additive effect in subjects with type 1 diabetes and AITD [34] .
As to the clinical implications of the present data, the measurement of GAD-Ab is strongly recommended if a young subject with Graves' disease shows hyperglycemia and symptoms related to diabetes. On the other hand, as Graves' disease is often complicated later without typical symptoms in subjects having type 2 diabetes, one should be alert to minor signs of thyrotoxicosis.
Measurement of GAD-Ab would be helpful to ascertain that both diseases coexist incidentally.
We conclude that GAD-Ab measurement could discriminate between the immunologically-related and incidental coexistence of diabetes and Graves' disease, although it remains to be elucidated whether additional measurement of other autoantibodies toward pancreatic B cell may help further discrimination.
